Free Trial
NASDAQ:CELU

Celularity (CELU) Stock Price, News & Analysis

Celularity logo
$2.94 +0.02 (+0.68%)
(As of 11/20/2024 ET)

About Celularity Stock (NASDAQ:CELU)

Key Stats

Today's Range
$2.77
$3.06
50-Day Range
$1.38
$3.83
52-Week Range
$1.30
$7.97
Volume
120,755 shs
Average Volume
3.18 million shs
Market Capitalization
$64.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Celularity Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
11th Percentile Overall Score

CELU MarketRank™: 

Celularity scored higher than 11% of companies evaluated by MarketBeat, and ranked 931st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Celularity.

  • Percentage of Shares Shorted

    6.92% of the float of Celularity has been sold short.
  • Short Interest Ratio / Days to Cover

    Celularity has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Celularity has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Celularity does not currently pay a dividend.

  • Dividend Growth

    Celularity does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.92% of the float of Celularity has been sold short.
  • Short Interest Ratio / Days to Cover

    Celularity has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Celularity has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Celularity has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Celularity this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for CELU on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Celularity to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Celularity insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.70% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 19.02% of the stock of Celularity is held by institutions.

  • Read more about Celularity's insider trading history.
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

CELU Stock News Headlines

“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
Celularity Inc. (NASDAQ:CELU) Sees Large Increase in Short Interest
Celularity raises FY24 revenue view to $54M-$60M from $50M-$56M
See More Headlines

CELU Stock Analysis - Frequently Asked Questions

Celularity's stock was trading at $2.4740 at the beginning of 2024. Since then, CELU stock has increased by 18.8% and is now trading at $2.94.
View the best growth stocks for 2024 here
.

Celularity Inc. (NASDAQ:CELU) issued its earnings results on Wednesday, October, 16th. The company reported ($1.03) EPS for the quarter. The business earned $14.68 million during the quarter. Celularity had a negative trailing twelve-month return on equity of 92.48% and a negative net margin of 264.30%.

Celularity's stock reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional shareholders of Celularity include Geode Capital Management LLC (0.63%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri.
View institutional ownership trends
.

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/16/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CELU
Fax
N/A
Employees
220
Year Founded
N/A

Profitability

Net Income
$-196,290,000.00
Net Margins
-264.30%
Pretax Margin
-264.28%

Debt

Sales & Book Value

Annual Sales
$42.69 million
Cash Flow
$8.91 per share
Book Value
$2.11 per share

Miscellaneous

Free Float
17,434,000
Market Cap
$64.64 million
Optionable
Optionable
Beta
0.51
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CELU) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners